"We will continue to execute and remain laser-focused as we now set our sights on year-end commitments, including the upcoming launch of our biosimilar to Herceptin®, Ogivri™, and as we continue to make progress toward a successful deal close with Pfizer's Upjohn business, which we continue to expect will occur in mid-2020."
President Rajiv Malik führt weiter aus:
"During the third quarter, we benefited from continued momentum on key products, including Yupelri®, Copaxone®, Fulphila® and Wixela™ Inhub™. We also were pleased with the overall performance of our global key brands and anticipate continued growth across these areas of our portfolio as we head into the fourth quarter. We expect to finish the year from a position of strength as we have reached all of the product milestones necessary to meet our performance commitments, including approval on our Ogivri™ product, which we expect to launch in the coming weeks."
Folglich bleibt vielleicht noch ein bißchen Zeit, sich die Aktie günstig ins Körbchen zu legen.
Doch getreu dem Motto....nur der frühe Vogel fängt den Wurm, bin ich schon dabei und im Plus!
Die Freiheit des Menschen liegt nicht darin, daß er tun kann, was er will, sondern das er nicht tun muß, was er nicht will.